Management of facial erythema of rosacea: What is the role of topical α-adrenergic receptor agonist therapy?

Journal of the American Academy of Dermatology

Volumn 69, Issue 6 SUPPL.1, 2013, Pages

  Del Rosso, James Q ^a,b,c  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

adrenergic receptor agonist; brimonidine; facial erythema; papules; pustules; rosacea; topical therapy

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BRIMONIDINE; DECONGESTIVE AGENT; METRONIDAZOLE; OXYMETAZOLINE; TETRACYCLINE DERIVATIVE; XYLOMETAZOLINE;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; ERYTHEMA; FACE ERYTHEMA; HUMAN; OPEN ANGLE GLAUCOMA; PAPULE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUSTULE; ROSACEA; SINGLE DRUG DOSE; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SKIN IRRITATION; TACHYPHYLAXIS; VASCULARIZATION; VASODILATATION;

EID: 84887858055     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.06.009     Document Type: Article

References (78)

1. J. Wilkin, M. Dahl, M. Detmar, L. Drake, A. Feinstein, and R. Odom Standardized classification system of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea J Am Acad Dermatol 46 2002 584 587
2. J. Wilkin, M. Dahl, M. Detmar, L. Drake, M.H. Liang, and R. Odom Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea J Am Acad Dermatol 50 2004 907 912
3. G.H. Crawford, M.T. Pelle, and W.D. James Rosacea I: etiology, pathogenesis, and subtype classification J Am Acad Dermatol 51 2004 327 341
4. J.Q. Del Rosso Advances in understanding and managing rosacea part 1: connecting the dots between pathophysiologic mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema J Clin Aesthet Dermatol 5 2012 16 25
5. J.Q. Del Rosso Advances in understanding and managing rosacea part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea J Clin Aesthet Dermatol 5 2012 26 36
6. M. Steinhoff, J. Buddenkotte, J. Aubert, M. Sulk, P. Novak, and V.D. Schwab Clinical, cellular, and molecular aspects in the pathophysiology of rosacea J Invest Dermatol 15 2011 2 11
7. V.D. Schwab, M. Sulk, S. Seeliger, P. Nowak, J. Aubert, and C. Mess Neurovascular and neuroimmune aspects in the pathophysiology of rosacea J Invest Dermatol 15 2011 53 62
8. K. Yamasaki, and R.L. Gallo Rosacea as a disease of cathelicidins and skin innate immunity J Invest Dermatol 15 2011 53 62
9. K. Yamasaki, A. Di Nardo, A. Bardan, M. Murakami, T. Ohtake, and A. Coda Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea Nat Med 13 2007 975 980
10. K. Yamasaki, and R.L. Gallo The molecular pathology of rosacea J Dermatol Sci 55 2009 77 81
11. A.B. Fleischer Inflammation in rosacea and acne: implications for patient care J Drugs Dermatol 10 2011 614 620
12. C.L. Bevins, and F.T. Liu Rosacea: skin innate immunity gone awry? Nat Med 13 2007 904 906
13. K. Yamasaki, K. Kanada, D.T. Macleod, A.W. Borkowski, S. Morizane, and T. Nakatsuji TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes J Invest Dermatol 131 2011 688 697
14. U. Meyer-Hoffert, and J.M. Schroder Epidermal proteases in the pathogenesis of rosacea J Invest Dermatol 15 2011 16 23
15. P.A. Gerber, B.A. Buhren, M. Steinhoff, and B. Homey Rosacea: the cytokine and chemokine network J Invest Dermatol 15 2011 40 47
16. Y. De, Q. Chen, A.P. Schmidt, G.M. Anderson, J.M. Wang, and J. Wooters LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells J Exp Med 192 2000 1069 1074
17. R. Koczulla, G. von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, and T. Gloe An angiogenic role for the human peptide antibiotic LL-37/hCAP-18 J Clin Invest 111 2003 1665 1672
18. A.H. Gomaa, M. Yaar, M.M. Eyada, and J. Bhawan Lymphangiogenesis and angiogenesis in non-phymatous rosacea J Cutan Pathol 34 2007 748 755
19. D.A. Guzman-Sanchez, Y. Ishiuji, T. Patel, J. Fountain, Y.H. Chan, and G. Yosipovitch Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea J Am Acad Dermatol 57 2007 800 805
20. P. Rosina, M. Zamperetti, A. Giovannini, C. Chieregato, and G. Girolomoni Videocapillaroscopic alterations in erythematotelangiectatic rosacea J Am Acad Dermatol 54 2006 100 104
21. H.J. Park, D.H. Cho, H.J. Kim, J.Y. Lee, B.K. Cho, and S.I. Bang Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37 J Invest Dermatol 129 2009 843 850
22. H.C. Korting, and C. Schollmann Tetracycline actions relevant to rosacea treatment Skin Pharmacol Physiol 22 2009 287 294
23. R. Huggenberger, and M. Detmar The cutaneous vascular system in chronic skin inflammation J Invest Dermatol 15 2011 24 32
24. G.S. Tjabringa, J. Aarbiou, D.K. Ninaber, J.W. Drijfhout, O.E. Sorensen, and N. Borregaard The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor J Immunol 171 2003 6690 6696
25. S. Tokumaru, K. Sayama, Y. Skirakata, H. Komatsuzawa, K. Ouhara, and Y. Hanakawa Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37 J Immunol 175 2005 4662 4668
26. J.T.M. Bamford Rosacea: current thoughts on origin Semin Cutan Med Surg 20 2001 199 206
27. M. Steinhoff, S. Stander, S. Seelinger, J.C. Ansel, M. Schmelz, and T. Luger Modern aspects of cutaneous neurogenic inflammation Arch Dermatol 139 2003 479 488
28. T. Dirschka, H. Tronnier, and R. Folster-Holst Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis Br J Dermatol 150 2004 1136 1141
29. M.A. McAleer, N. Lacey, and F.C. Powell The pathophysiology of rosacea G Ital Dermatol Venereol 144 2009 663 671
30. M.A. McAleer, P. Fitzpatrick, and F.C. Powell Papulopustular rosacea: prevalence and relationship to photodamage J Am Acad Dermatol 63 2010 33 39
31. Y.I. Bae, S.J. Yun, J.B. Lee, S.J. Kim, Y.H. Won, and S.C. Lee Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype Ann Dermatol 21 2009 243 249
32. M.O. Oztas, M. Balk, E. Ogus, M. Bozkurt, I.H. Ogus, and N. Ozer The role of free radicals in the etiopathogenesis of rosacea Clin Exp Dermatol 28 2003 188 192
33. V.S. Tisma, A. Basta-Juzbasic, M. Jaganjac, L. Brcic, I. Dobric, and J. Lipozencic Oxidative stress and ferritin expression in the skin of rosacea patients J Am Acad Dermatol 60 2009 270 276
34. Y.H. Jang, J.H. Sim, H.Y. Kang, Y.C. Kim, and E.S. Lee Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea J Eur Acad Dermatol Venereol 25 2011 544 548
35. E. Lazaridou, C. Giannopoulou, C. Fotiadou, E. Vakirlis, A. Trigoni, and D. Ioannides The potential role of microorganisms in the development of rosacea J Dtsch Dermatol Ges 9 2011 21 25
36. M. Reinholz, T. Ruzicka, and J. Scauber Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease Ann Dermatol 24 2012 126 135
37. Z.D. Draelos Treating beyond the histology of rosacea Cutis 74 Suppl 2004 28 31
38. J.Q. Del Rosso, H. Baldwin, and G. Webster American Acne and Rosacea Society rosacea medical management guidelines J Drugs Dermatol 7 2008 531 533
39. R. Odom, M. Dahl, J. Dover, Z. Draelos, L. Drake, and M. Macsai Standard management options for rosacea, part 2: options according to rosacea subtype Cutis 84 2009 97 104
40. M.T. Pelle, G.H. Crawford, and James WD. Rosacea II therapy J Am Acad Dermatol 51 2004 499 512
41. J.Q. Del Rosso, and E.W. Baum Comprehensive medical management of rosacea: an interim study report and literature review J Clin Aesthet Dermatol 1 2008 20 25
42. C. Kennedy Carney, W. Cantrell, and B.E. Elewski Rosacea: a review of current topical, systemic and light based therapies G Ital Dermatol Venereol 144 2009 673 688
43. J.Q. Del Rosso Medical treatment of rosacea with emphasis on topical therapies Expert Opin Pharmacother 5 2004 5 13
44. K.J. McClellan, and S. Noble Topical metronidazole: a review of its uses in rosacea Am J Clin Dermatol 1 2000 191 199
45. R.H. Liu, M.K. Smith, S.A. Basta, and E.R. Farmer Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials Arch Dermatol 142 2006 1047 1052
46. J.Q. Del Rosso, G.W. Webster, M. Jackson, M. Rendon, P. Rich, and H. Torok Two randomized phase II clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea J Am Acad Dermatol 56 2007 791 801
47. E. Neumann, and A. Frithz Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea Int J Dermatol 37 1998 263 266
48. A.N. Sapadin, and R. Fleischmajer Tetracyclines: non-antibiotic properties and their clinical implications J Am Acad Dermatol 54 2006 258 265
49. J.Q. Del Rosso Anti-inflammatory dose doxycycline in the treatment of rosacea J Drugs Dermatol 8 2009 664 668
50. G.F. Webster An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) Cutis 86 Suppl 2010 7 15
51. J.Q. Del Rosso, and N. Bhatia Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application Cutis 88 2011 67 72
52. J.Q. Del Rosso, S. Bruce, M. Jarratt, A. Menter, and G. Staedtler Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea J Drugs Dermatol 9 2010 607 613
53. K.N. Kanada, T. Nakatsuji, and R.L. Gallo Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin J Invest Dermatol 132 2012 1435 1442
54. Y. Karincaoglu, N. Bayram, O. Aycan, and M. Esrefoglu The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms J Dermatol 31 2004 618 626
55. R.R. Bonamigo, L. Bakos, M. Edelweiss, and A. Cartell Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Dermatol Venereol 19 2005 646 647
56. S.A. Buechner Rosacea: an update Dermatology 210 2005 100 108
57. C. Hansen, J.J. Leitenberger, and H.T. Jacobe Photoimmunology A.A. Gaspari, S.K. Tyring, Clinical and basic immunology 2008 Springer-Verlag London 147 155
58. W.D. James, T.G. Berger, and D.M. Elston Skin: basic structure and function W.D. James, T.G. Berger, D.M. Elston, Andrews' diseases of the skin clinical dermatology 10th ed. 2006 Saunder Elsevier Philadelphia (PA) 12
59. L.B. Rowell Reflex control of the cutaneous vasculature J Invest Dermatol 69 1977 154 166
60. J.M. Johnson, and D.L. Kellogg Local thermal control of human cutaneous circulation J Appl Physiol 109 2010 1229 1238
61. 1-adrenergic receptor antagonist, oxymetazoline Arch Dermatol 143 2007 1369 1371
62. B. Civantos Calzada, and A. Aleixandre de Artinano Alpha-adrenoreceptor subtypes Pharmacol Res 44 2001 195 208
63. S. Guimaraes, and D. Moura Vascular adrenoreceptors: an update Pharmacol Rev 53 2001 319 356
64. C.J. Leech, and J.E. Faber Different alpha-adrenoreceptor subtypes mediate constriction of arterioles and venules Am J Physiol 270 1996 H710 H722
65. J.P. Hieble Subclassification and nomenclature of alpha- and beta-adrenoreceptors Curr Top Med Chem 7 2007 129 134
66. M.T. Piascik, and D.M. Perez Alpha1-adrenergic receptors: new insights and directions J Pharmacol Exp Ther 298 2001 403 410
67. J.H. Kim, Y.S. Oh, J.H. Ji, H. Bak, and S.K. Ahn Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline J Dermatol 38 2011 510 513
68. J. Fowler, M. Jarratt, A. Moore, K. Meadows, A. Pollack, and M. Steinhoff Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies Br J Dermatol 166 2012 633 641
69. K. Mark, R.M. Sparacio, A. Voigt, K. Marenus, and D.S. Sarnoff Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment Dermatol Surg 29 2003 600 604
70. P. Papageorgiou, W. Clayton, S. Norwood, S. Chopra, and M. Rustin Treatment of rosacea with intense pulsed light: significant treatment and long-lasting results Br J Dermatol 159 2008 628 632
71. I.M. Neuhaus, L.T. Zane, and W.D. Tope Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea Dermatol Surg 35 2009 920 928
72. S.M. Clark, S.W. Lanigan, and R. Marks Laser treatment of erythema and telangiectasia associated with rosacea Lasers Med Sci 17 2002 26 33
73. S.R. Tan, and W.D. Tope Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life J Am Acad Dermatol 51 2004 592 599
74. N. Menezes, A. Moreira, G. Mota, and A. Baptista Quality of life of rosacea: pulsed dye laser impact J Cosmet Laser Ther 11 2009 139 141
75. M. Berg, and D.W. Edstrom Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea Lasers Surg Med 34 2004 266 268
76. J. Fowler, M. Jackson, and A. Moore Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies J Drugs Dermatol 12 2013 650 656
77. Demirli R, Otto P, Viswanathan R. RBX technology overview, Canfield Imaging Systems, Canfield Scientific, Fairfield, NJ, white paper. Available from: URL: http://www.canfieldscientific.com. Accessed August 25, 2012.
78. M. Detmar, L.F. Brown, K.P. Claffey, K.T. Yeo, O. Kocher, and R.W. Jackman Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis J Exp Med 180 1994 1141 1146